These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25879583)

  • 1. Lack of in vivo antibody dependent cellular cytotoxicity with antibody containing gold nanoparticles.
    Ahmed M; Pan DW; Davis ME
    Bioconjug Chem; 2015 May; 26(5):812-6. PubMed ID: 25879583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
    Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.
    Kasper S; Breitenbuecher F; Reis H; Brandau S; Worm K; Köhler J; Paul A; Trarbach T; Schmid KW; Schuler M
    Oncogene; 2013 Jun; 32(23):2873-81. PubMed ID: 22797062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
    Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
    Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
    Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P
    Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo.
    Khan JA; Kudgus RA; Szabolcs A; Dutta S; Wang E; Cao S; Curran GL; Shah V; Curley S; Mukhopadhyay D; Robertson JD; Bhattacharya R; Mukherjee P
    PLoS One; 2011; 6(6):e20347. PubMed ID: 21738572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.
    Kawaguchi Y; Kono K; Mimura K; Sugai H; Akaike H; Fujii H
    Int J Cancer; 2007 Feb; 120(4):781-7. PubMed ID: 17096332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
    Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
    Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
    Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
    Levy EM; Sycz G; Arriaga JM; Barrio MM; von Euw EM; Morales SB; González M; Mordoh J; Bianchini M
    Innate Immun; 2009 Apr; 15(2):91-100. PubMed ID: 19318419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles.
    Curley SA; Cherukuri P; Briggs K; Patra CR; Upton M; Dolson E; Mukherjee P
    J Exp Ther Oncol; 2008; 7(4):313-26. PubMed ID: 19227011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
    Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
    Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer.
    Ashton JR; Gottlin EB; Patz EF; West JL; Badea CT
    PLoS One; 2018; 13(11):e0206950. PubMed ID: 30408128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
    Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
    J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles.
    Tummala S; Kumar MN; Pindiprolu SK
    Drug Deliv; 2016 Nov; 23(9):3505-3519. PubMed ID: 27295176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
    Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
    Murray JC; Aldeghaither D; Wang S; Nasto RE; Jablonski SA; Tang Y; Weiner LM
    Cancer Immunol Res; 2014 Dec; 2(12):1186-98. PubMed ID: 25300860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
    Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
    Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
    Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
    Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.